Previous CGM studies on insulin-treated patients have reported that RF is associatedwith an increased percentage of time spent in hyperglycemia and a reduced percentageof time spent in the target range.19,22 Nonetheless, several studiesreported fewer hypoglycemia episodes and improved glycemic variabilities amongCSII-treated patients,2,17 which could be attributed to the benefits of reducing basalinsulin infusion rates or suspending it to avoid hypoglycemia episodes during fasting.16 The gene discussed is INS; the disease is Hypoglycemia.